Complementary gene regulation by NRF1 and NRF2 protects against hepatic cholesterol overload

(Cell Reports 42, 112399; April 25, 2023) In the originally published version of this article, in the Figure 6G, we unintentionally displayed the same representative image for male sample (row 6, column 2) in the spot for the female sample (row 6, column 4). Please note the corresponding quantitation, interpretation, and result is still correct. Additionally, when we published this study, we also published the images for each figure in the Mendeley Data repository (https://data.mendeley.com/datasets/pw77wmhss9/1). Therein, you will find a subfolder in Folder “Figure 6G”. Within that is the collected images as well as separate folders for representative images. In the folder “Rep images N1N2 Cholesterol crystals”, you will see the image file “22M N1N2 HFFC & R CRE BARD 1”, for which the “M” is for the male sample, and for which we unintentionally duplicated and displayed in the spot for the female sample. We had meant to put the image file “21F N1N2 HFFC & R CRE BARD 1” (the “F” is for female) in the female sample. A new figure has been generated in which the correct representative samples are shown. The authors regret this error.Figure 6GHepatocyte NRF1 and NRF2 contribute to therapeutic effects of bardoxolone (original)View Large Image Figure ViewerDownload Hi-res image Download (PPT) Complementary gene regulation by NRF1 and NRF2 protects against hepatic cholesterol overloadAkl et al.Cell ReportsApril 14, 2023In BriefAkl et al. show that combined hepatocyte NRF1 and NRF2 deficiency accelerates the onset of cholesterol accumulation and crystallization and steatohepatitis and that combined induction of NRF1 and NRF2 ameliorates steatosis and inflammation in nutrient-overloaded liver. Their findings indicate that therapies targeting both transcriptional factors may be efficacious for treating metabolic-associated steatohepatitis. Full-Text PDF Open Access